本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 安徽华恒生物科技股份有限公司（以下简称"公司"）第四届监事会第六次 会议，于 2023 年 8 月 28 日在公司会议室，以现场会议结合通讯方式召开。临时 会议通知已于 2023 年 8 月 18 日以专人递送方式送达。本次会议应到监事 3 人， 实到监事 3 人。会议由监事会主席刘洋召集和主持。本次会议的召集、召开符合 《中华人民共和国公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 证券代码：688639 证券简称：华恒生物 公告编号：2023-047 安徽华恒生物科技股份有限公司 第四届监事会第六次会议决议公告 （二）审议通过《关于公司 2023 年半年度募集资金存放与实际使用情况的 专项报告的议案》 监事会认为：公司 2023 年半年度募集资金存放和使用情况符合相关法律、 法规和制度文件的规定，公司对募集资金进行了专户存储和专项使用。本公司监 事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性 ...

二、关于公司前次募集资金使用情况专项报告的议案 安徽华恒生物科技股份有限公司 独立董事关于第四届董事会第七次会议 相关事项的独立意见 根据《中华人民共和国公司法》《上市公司独立董事规则》《上海证券交易所 科创板上市公司自律监管指引第1号——规范运作》等相关法律法规、规章制度及 《安徽华恒生物科技股份有限公司章程》《安徽华恒生物科技股份有限公司独立董 事工作制度》有关规定，我们作为安徽华恒生物科技股份有限公司（以下简称"公 司")的独立董事，本着认真、严谨、负责的态度，对公司于2023年8月28日召开的 第四届董事会第七次会议审议的相关议案及事项发表如下独立意见： 一、关于公司2023年半年度募集资金存放与实际使用情况的专项报告的议案 独立董事认为：公司2023年半年度募集资金存放与实际使用情况符合《上市公 司监管指引第2号——上市公司募集资金管理和使用的监管要求》《上海证券交易 所科创板上市公司自律监管指引第1号——规范运作》《上海证券交易所科创板股 票上市规则》等相关规定，公司对募集资金进行了专户存储和专项使用，不存在变 相改变募集资金用途和损害股东利益的情形，也不存在募集资金使用违反相关法律 法规的情形。 ...

2023 年第一季度报告 单位：元 币种：人民币 证券代码：688639 证券简称：华恒生物 安徽华恒生物科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人郭恒华、主管会计工作负责人樊义及会计机构负责人朱修发（会计主管人员）保证季 度报告中财务信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|--------------------------------------| | 项目 | 本报告期 | 本报告期比上年 同期增减变动幅 度 (%) | | 营业收入 | 400,254 ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,418.65 million, an increase of 48.69% compared to 2021[25]. - The net profit attributable to shareholders for 2022 was CNY 320.03 million, reflecting a 90.23% increase year-over-year[25]. - The net cash flow from operating activities increased by 273.47% to CNY 357.43 million, primarily due to increased cash receipts from sales[25]. - Total assets grew by 37.51% to CNY 2,027.09 million at the end of 2022, driven by increased fixed asset investments[25]. - Basic earnings per share for 2022 were CNY 2.95, up 73.53% from 2021[24]. - The net profit after deducting non-recurring gains and losses was CNY 303.65 million, a 108.95% increase year-over-year[23]. - The company achieved total revenue of 1,418.65 million yuan in 2022, representing a year-on-year growth of 48.69%[35]. - The net profit attributable to the parent company was 320.03 million yuan, with a year-on-year increase of 90.23%[35]. - Total assets reached 2,027.09 million yuan, up 37.51% year-on-year, while equity attributable to the parent company increased by 25.13% to 1,480.49 million yuan[35]. Dividend and Share Capital - The company plans to distribute a cash dividend of 9.00 RMB per 10 shares, totaling approximately 97,560,000 RMB, which represents 30.48% of the net profit attributable to shareholders for 2022[7]. - The company intends to increase its total share capital by 48,780,000 shares through a capital reserve transfer, resulting in a new total of 157,180,000 shares[7]. - The cash dividend policy is designed to protect the rights of minority investors and has not been adjusted during the reporting period[183]. - The company has maintained a consistent cash dividend policy that aligns with its articles of association and shareholder resolutions[187]. Research and Development - The company’s R&D expenditure accounted for 5.54% of operating revenue in 2022, consistent with the previous year[24]. - The company achieved a significant increase in R&D investment, totaling approximately ¥78.61 million, which represents a 48.76% increase compared to the previous year[71]. - The total number of newly added patents during the reporting period includes 17 invention patents and 24 utility model patents, bringing the cumulative total to 188 invention patents and 68 utility model patents[69]. - The company has established three major R&D centers, enhancing its synthetic biology research capabilities and covering the entire industrial chain from strain construction to large-scale production[36]. - The company is focusing on research and development to introduce new products in the upcoming fiscal year[159]. - The company has established a comprehensive talent development system, including various training programs to align with its long-term strategic goals[182]. Market Position and Strategy - The company has established itself as a leading producer of amino acids, with significant market share in both domestic and international markets[139]. - The company is focused on expanding its market share in the L-valine sector, where competition is intensifying[99]. - The company is actively exploring new market demands and applications for its products, particularly in emerging markets[50]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[162]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[159]. Governance and Compliance - The board of directors and management have confirmed the accuracy and completeness of the annual report[4]. - The company adheres to legal and regulatory requirements for corporate governance, ensuring clear responsibilities among shareholders, board members, and management[151]. - There were no significant discrepancies in corporate governance compared to regulatory requirements, maintaining independence in business operations[151]. - The company has maintained compliance with shareholder meeting procedures, ensuring all resolutions were passed without objection[154]. - The company has a structured remuneration decision process for directors and senior management, with oversight from the compensation and assessment committee[167]. Operational Efficiency - The company has implemented a production model combining "sales-driven production" and "reasonable inventory," improving operational efficiency[48]. - The company has implemented standardized management practices in its sales department to enhance operational efficiency and market responsiveness[50]. - The company is focused on optimizing its production processes to reduce costs and improve the robustness of its strains for industrial applications[53]. - The company has established a comprehensive salary and performance incentive system to enhance talent attraction and employee motivation[180]. Risk Management - The company has disclosed detailed risk factors in the management discussion and analysis section of the report[4]. - The company faces risks related to technological obsolescence, as it relies on fermentation and enzyme-catalyzed production processes[88]. - The company is exposed to raw material price fluctuations, which could adversely affect its operating performance if not managed effectively[91]. - The company has a significant amount of accounts receivable, which poses a risk if not managed properly as sales expand[95]. - The company is actively monitoring changes in the international trade environment, which could impact its operations and profitability[100]. Sustainability and Innovation - The company is committed to using renewable biological resources to replace non-renewable petrochemical resources, aligning with sustainable development goals[142]. - The company has successfully implemented a biological manufacturing method that significantly reduces energy consumption and enhances product competitiveness[140]. - The management team emphasized the importance of sustainability in their future strategies, aiming for a 30% reduction in carbon emissions by 2025[163]. - The company has introduced innovative methods for the treatment and recovery of waste from L-alanine production, enhancing sustainability[64].